January 16, 2024

The Honorable Charles Schumer
Majority Leader
US Senate
S-221 Capitol Building
Washington, DC 20510

The Honorable Mitch McConnell
Minority Leader
US Senate
S-230 Capitol Building
Washington, DC 20510

The Honorable Mike Johnson
Speaker of the House
US House of Representatives
H-232 Capitol Building
Washington, DC 20515

The Honorable Hakeem Jeffries
Minority Leader
US House of Representatives
H-204 Capitol Building
Washington, DC 20515

Re: The Urgent Need to Reauthorize PAHPA

Dear Leaders Schumer and McConnell, Speaker Johnson, and Leader Jeffries,

On behalf of the undersigned organizations, we write to express our strong desire to see the Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorized in the same bipartisan fashion it has been supported since the original authorization 17 years ago.

As you know, PAHPA underpins Department of Health and Human Services (HHS) agencies, programs, and funding authorizations for addressing national health security threats. PAHPA created the HHS Assistant Secretary for Preparedness and Response (now the Administration for Strategic Preparedness and Response) and the Biomedical Advanced Research and Development Authority (BARDA) and provides important congressional oversight and direction to federal programs related to early warning, prevention, preparedness, and response.

This overall framework expired on September 30, 2023, requiring stopgap, temporary extensions in the continuing resolution. We encourage Congress to include a comprehensive five-year PAHPA reauthorization in the next moving legislative vehicle.

The last three PAHPA bills all shared major recurring themes: they all adjusted to the changing threat landscape, focused on challenges identified since the prior bill, and considerably strengthened our nation’s health security with each reauthorization.

Our nation’s changing health security threat landscape and the federal government’s responsibility to protect the American people demand that we work together now to find a strong bipartisan path forward to reauthorize this critical legislation. Whether the next health security threat is naturally occurring, the result of an accident, or intentionally caused, our country must be in a better position to prevent, prepare for, and respond to such incidents.

Failing to reauthorize PAHPA would have serious effects on our country’s economic wellbeing, national security, and health security given the rapidly changing threat landscape.

We are hopeful that PAHPA will remain a strong bipartisan legislative framework, as it has always been. We stand ready to assist you in whatever ways we can to help get this important law reauthorized this year.
Sincerely (in alphabetical order),

1Day Sooner
3M
Acadian Ambulance Service, Inc.
Adaptive Phage Therapeutics
AdvaMed
Aequor Inc.
Alliance for Biosecurity
Altor Safety
America's Essential Hospitals
American Ambulance Association
American Association of Neurological Surgeons
American Clinical Laboratory Association
American College of Emergency Physicians
American College of Surgeons
American Hospital Association
American Lung Association
American Medical Manufacturers Association (AMMA)
American Pharmacies
American Public Health Association
American Society for Microbiology
Arizona Bioindustry Association, Inc. (AZBio)
Association for Professionals in Infection Control and Epidemiology
Association of American Medical Colleges
Association of Maternal & Child Health Programs
Association of Public Health Laboratories
Association of State and Territorial Health Officials
Asthma and Allergy Foundation of America
AstraZeneca Pharmaceuticals
ATCC
Atea Pharmaceuticals, Inc.
Bavarian Nordic
Big Cities Health Coalition
Biocom California
BioCT
BioForward Wisconsin
BioKansas
BioNJ
Biotechnology Innovation Organization (BIO)
Bugworks
Cencora
Civitas Networks for Health
Colorado BioScience Association
CommonSpirit Health
Congress of Neurological Surgeons
Council of State and Territorial Epidemiologists
Council of State Bioscience Associations (CSBA)
CSL Seqirus
Emergency Department Practice Management Association
Emergent BioSolutions
FAH
Federation of American Scientists
FluGen Inc.
Georgia Bio
Gerontological Society of America
Ginkgo Bioworks
Global Health Investment Corporation
Global Health Technologies Coalition
Gryphon Scientific
<table>
<thead>
<tr>
<th>Organization Name</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>GSK</td>
<td>New Orleans BioInnovation Center</td>
</tr>
<tr>
<td>Health Industry Distributors Association (HIDA)</td>
<td>NewYorkBIO</td>
</tr>
<tr>
<td>Healthcare Distribution Alliance</td>
<td>NightHawk Biosciences</td>
</tr>
<tr>
<td>Healthcare Leadership Council</td>
<td>Novavax</td>
</tr>
<tr>
<td>Healthcare Ready</td>
<td>Ochsner Health</td>
</tr>
<tr>
<td>Helix</td>
<td>Ohio Life Sciences Association</td>
</tr>
<tr>
<td>HIMSS</td>
<td>Oklahoma Bioscience Association</td>
</tr>
<tr>
<td>HIV Medicine Association</td>
<td>PDS Biotechnology</td>
</tr>
<tr>
<td>IAVI</td>
<td>PharmaJet Inc.</td>
</tr>
<tr>
<td>Illinois Biotechnology Innovation Organization</td>
<td>Premier Inc.</td>
</tr>
<tr>
<td>Indiana Health Industry Forum</td>
<td>Public Health Accreditation Board</td>
</tr>
<tr>
<td>Infectious Diseases Society of America</td>
<td>READDI Inc.</td>
</tr>
<tr>
<td>INOVIO Pharmaceuticals</td>
<td>Research!America</td>
</tr>
<tr>
<td>Institute for Progress</td>
<td>SAB Biotherapeutics, Inc.</td>
</tr>
<tr>
<td>Johns Hopkins Center for Health Security</td>
<td>Sanofi</td>
</tr>
<tr>
<td>Life Sciences PA</td>
<td>SecureBio</td>
</tr>
<tr>
<td>Locus Biosciences</td>
<td>Shionogi Inc.</td>
</tr>
<tr>
<td>Mallinckrodt</td>
<td>SIGA Technologies, Inc.</td>
</tr>
<tr>
<td>Marked By Covid</td>
<td>Society for Public Health Education</td>
</tr>
<tr>
<td>Mass General Brigham</td>
<td>Soligenix, Inc.</td>
</tr>
<tr>
<td>MassBio</td>
<td>Technologies for Pandemic Defense</td>
</tr>
<tr>
<td>McKesson</td>
<td>Texas A&amp;M Health Science Center</td>
</tr>
<tr>
<td>Medical Alley</td>
<td>Texas Healthcare &amp; Bioscience Institute</td>
</tr>
<tr>
<td>Medical Countermeasures Coalition</td>
<td>Tonix Pharmaceuticals</td>
</tr>
<tr>
<td>Missouri Biotechnology Association (MOBIO)</td>
<td>Trinity Health</td>
</tr>
<tr>
<td>Morehouse School of Medicine - Atlanta, GA</td>
<td>TrippBio, Inc.</td>
</tr>
<tr>
<td>Mount Sinai Health System</td>
<td>Trust for America’s Health</td>
</tr>
<tr>
<td>National Association of County and City Health Officials</td>
<td>United Safety Technology Inc</td>
</tr>
<tr>
<td>National Immigration Law Center</td>
<td>United States Pharmacopeia (USP)</td>
</tr>
<tr>
<td>NC Life Sciences Organization</td>
<td>University of Hawaii</td>
</tr>
<tr>
<td>New Mexico Biotechnology &amp; Biomedical Association (NMBio)</td>
<td>University of Maryland School of Medicine</td>
</tr>
<tr>
<td>New Orleans BioInnovation Center</td>
<td>Valneva USA</td>
</tr>
</tbody>
</table>
Vaxess Technologies
Vaxxas Inc
Virginia Biotechnology Association
Washington State University

CC:
Chair Bernie Sanders
Health, Education, Labor & Pensions Committee
US Senate

Ranking Member Bill Cassidy
Health, Education, Labor & Pensions Committee
US Senate

Chair Cathy McMorris Rodgers
Energy & Commerce Committee
US House of Representatives

Ranking Member Frank Pallone
Energy & Commerce Committee
US House of Representatives